Exclusive: Holoclara raises $16 million Series A to develop therapeutics—with worms
Summary
Kairos Ventures is a previous investor.If youre wondering why all the fuss, the answers pretty simple: In the scientific sense, worms are rather special.Its the one organism that I would say is the simplest, that we know the most about, and thats why youve seen so many Nobel Prizes from C. elegans [roundworms], said Choe. Dont forget, you lay it flat on a microscope, on a thin sheet of agar, with a tiny drop of anesthetic and itll just go to sleep on its sideyou can then zap with a laser any single cell or neuron you want.So, thats what Holoclara is chasingthat for even debilitating allergies and autoimmune disorders, there could be treatments and medications built on worm molecules. Sound Ventures led the round and was joined by M13, SignalFire, and Next View Ventures.- Adonis, a New York City-based revenue intelligence and automation platform designed for health care, raised $31 million in Series B funding. Point72 Private Investments led the round and was joined by Kin Ventures and existing investors General Catalyst, Bling Capital, and Max Ventures.- Sensi.AI, a Palo Alto, Calif.-based AI copilot for caregivers, raised $31 million in Series B funding. New Enterprise Associates, Wing VC, and WndrCo led the round and were joined by Pear VC.- Rainforest, an Atlanta, Ga.-based embedded payment processor for software platforms, raised $20 million in Series A funding.